Emirhan Harbi

Dr. Emirhan Harbi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
EHEmirhan Harbi
Emirhan Harbi
MAMichael Aschner
Michael Aschner

10 December 2024 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
EHEmirhan Harbi
Emirhan Harbi
MAMichael Aschner
Michael Aschner

5 March 2025 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
EHEmirhan Harbi
Emirhan Harbi
MAMichael Aschner
Michael Aschner

5 September 2024 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
EHEmirhan Harbi
Emirhan Harbi
MAMichael Aschner
Michael Aschner

29 July 2025 in Neurochemical Research
Verified
Journal Article
Closed access
EHEmirhan Harbi
Emirhan Harbi
EYErhan Yarar
Erhan Yarar
CMChristopher E. Mason
Christopher E. Mason
MAMichael Aschner
Michael Aschner
AAAytug Altundag
Aytug Altundag

1 August 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
EHEmirhan Harbi
Emirhan Harbi
Christopher MasonChristopher Mason
Christopher Mason
Gliomas are a type of CNS tumors. Protein arginine methyltransferases (PRMTs) play important epigenetic regulatory roles in various cancers, including gliomas, by regulating DNA repair and cellular signaling pathways. Recent studies have also identified overexpression of PRMTs in gliomas and have shown that it is associated with tumor progression and resistance to conventional therapies. Targeting PRMTs has shown promising preclinical results demonstrating the potential to disrupt tumor growth, enhance DNA damage responses, and improve the sensitivity of gliomas to radiotherapy and temozolomide. In this review, we focus on the translational and clinical relevance of PRMT inhibitors in glioma subtypes, highlighting their latest clinical developments and ongoing clinical trials. Unlike previous reviews, our article provides an updated synthesis of clinical data, discusses challenges and opportunities in clinical translation, and suggests future directions for integrating PRMT inhibitors into glioma therapy.